Back to results
US 10,471,103 B2Granted
Methods to improve cell therapy
AssigneeThe Brigham and Women's Hospital, Inc.
InventorRobert Sackstein
Life of this patent
Estimating the term…
Abstract
Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.
Claims5
A method of enhancing pancreatic infiltration of intravenously administered mesenchymal stem cells (MSCs) in a subject having type 1 diabetes, the method comprising:
- administering to the subject a population of MSCs modified, ex vivo, with at least one glycosyltransferase effective to increase expression of an Hematopoietic Cell E-/L-selectin Ligand (HCELL), the population expressing the HCELL at a level that exceeds the level of expression of a native population of the MSCs,
- wherein said cell administration occurs coincident with E-selectin expression on endothelial cells within the pancreatic tissue of the subject and/or coincident with accumulation of leukocytes within the pancreatic tissue of the subject;
- wherein the administering enhances the pancreatic infiltration of the intravenously administered MSCs relative to that of the unmodified MSCs and provides an anti-diabetic effect to the subject.
Dependencies are inferred from the claim text.